Market Place
Sourcing Support
Disc Medicine to Participate in Upcoming Investor Conferences
13 Nov 2024 //
GLOBENEWSWIRE
Disc Medicine Secures $200M Non-Dilutive Debt from Hercules
08 Nov 2024 //
GLOBENEWSWIRE
Disc Medicine Announces ASH Presentations Across Portfolio
05 Nov 2024 //
GLOBENEWSWIRE
Disc Medicine Announces Successful Ph 2 Meeting for Bitopertin
04 Nov 2024 //
GLOBENEWSWIRE
Disc Host Call on Ph 2 FDA Meeting for Bitopertin in Protoporphyria
01 Nov 2024 //
GLOBENEWSWIRE
Disc Medicine Presents Data on CKD and Anemia at ASN Kidney Week
25 Oct 2024 //
GLOBENEWSWIRE
Disc Medicine Appoints Rahul Kaushik as CTO
23 Oct 2024 //
GLOBENEWSWIRE
Disc Medicine Presents DISC-0974 Data In CKD At ASN Kidney Week 2024
11 Oct 2024 //
GLOBENEWSWIRE
Disc Medicine Appoints Steve Caffé As Chief Regulatory Officer
19 Sep 2024 //
GLOBENEWSWIRE
Disc Medicine to Participate in Upcoming Investor Conferences
30 Aug 2024 //
GLOBENEWSWIRE
Disc Medicine Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Disc Medicine Presents Portfolio Data At EHA 2024 Congress
14 Jun 2024 //
GLOBENEWSWIRE
Disc Medicine Announces Underwritten Offering of Common Stock
14 Jun 2024 //
GLOBENEWSWIRE
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
30 May 2024 //
GLOBENEWSWIRE
Disc Medicine Announces EHA 2024 Congress Portfolio Presentations
14 May 2024 //
GLOBENEWSWIRE
Disc Medicine To Participate In H.C. Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
Disc Medicine Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Disc Reports Topline Results from Ph 2 Study of Bitopertin in Patients with EPP
01 Apr 2024 //
GLOBENEWSWIRE
Disc blames `outsized` placebo response on mixed Pha 2 data rare blood disorder
01 Apr 2024 //
ENDPTS
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Disc Medicine to Participate in the Leerink Partners Biopharma Conference 2024
06 Mar 2024 //
GLOBENEWSWIRE
Disc Medicine Expands Leadership Team
26 Feb 2024 //
GLOBENEWSWIRE
Disc Medicine Receives FDA Fast Track Designation for DISC-0974
20 Feb 2024 //
GLOBENEWSWIRE
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405
09 Feb 2024 //
GLOBENEWSWIRE
Disc Medicine Strengthens Leadership Team
07 Feb 2024 //
GLOBENEWSWIRE
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Disc Announces Retirement of Brian MacDonald as Chief Innovation Officer
20 Dec 2023 //
GLOBENEWSWIRE
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974
11 Dec 2023 //
GLOBENEWSWIRE
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin
11 Dec 2023 //
GLOBENEWSWIRE
Disc Announces Grant of Patent for Treating Erythropoietic Protoporphyrias
14 Nov 2023 //
GLOBENEWSWIRE
Disc Medicine Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Disc Medicine to Participate in Upcoming Investor Conferences
08 Nov 2023 //
GLOBENEWSWIRE
Disc Medicine Announces Multiple Presentations Across Portfolio
02 Nov 2023 //
GLOBENEWSWIRE
Disc Medicine Announces Planned Departure of CFO Joanne Bryce
23 Oct 2023 //
GLOBENEWSWIRE
Disc Medicine Initiates a Phase 1 Study of DISC-3405
03 Oct 2023 //
GLOBENEWSWIRE
Disc Medicine Receives FDA Fast Track Designation for MWTX-003
20 Sep 2023 //
GLOBENEWSWIRE
Disc Medicine to Participate in Upcoming Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Disc Medicine Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Trial of Bitopertin
27 Jul 2023 //
GLOBENEWSWIRE
Disc Medicine Announces Closing of Public Offering of Common Stock
22 Jun 2023 //
GLOBENEWSWIRE
With PhII blood disorder data in hand, Disc seeks $100M in public offering
13 Jun 2023 //
ENDPTS
Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock
13 Jun 2023 //
GLOBENEWSWIRE
Disc Medicine Announces Proposed Public Offering of Common Stock
12 Jun 2023 //
GLOBENEWSWIRE
Disc Medicine claims PII win for repurposed ex-Roche drug in rare blood disorder
09 Jun 2023 //
ENDPTS
Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin
09 Jun 2023 //
GLOBENEWSWIRE
Disc Medicine to Participate in the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Disc Medicine Reports 1Q 2023 FYR Results and Provides Business Update
15 May 2023 //
GLOBENEWSWIRE
Disc Announces Presentation of Data from PII BEACON Trial in Patients with EPP
11 May 2023 //
GLOBENEWSWIRE
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
21 Apr 2023 //
GLOBENEWSWIRE
Disc to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)
13 Apr 2023 //
GLOBENEWSWIRE
Disc Medicine Reports Full Year 2022 Financial Results and Provides Update
31 Mar 2023 //
GLOBENEWSWIRE
Disc Medicine Announces Collaboration with NIH for PII Study of Bitopertin
21 Mar 2023 //
GLOBENEWSWIRE
Disc Medicine Initiates a Phase 1b/2 Study of DISC-0974 in Adults with NDD-CKD
16 Feb 2023 //
GLOBENEWSWIRE
Disc Medicine Announces $62.5M Financing led by Bain Capital Life Sciences
14 Feb 2023 //
GLOBENEWSWIRE
Disc Medicine to Participate in SVB Securities Global Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
Disc Medicine Announces Completion of Merger with Gemini Therapeutics
29 Dec 2022 //
BIOSPACE
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin
27 Dec 2022 //
PRNEWSWIRE
Disc Medicine Announces Several Presentations Across Hematology Portfolio at ASH
13 Dec 2022 //
PRNEWSWIRE
Disc Medicine Announces Multiple Presentations at the 64th ASH
03 Nov 2022 //
PRNEWSWIRE
Disc Medicine Initiates AURORA, a Phase 2 Study of Bitopertin with EPP
31 Oct 2022 //
PRNEWSWIRE
